| Completed | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian NCT03552471 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent O NCT02996825 | City of Hope Medical Center | Phase 1 |
| Completed | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid End NCT02684227 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Perit NCT02657928 | Mayo Clinic | Phase 2 |
| Completed | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malig NCT02578888 | Albert Einstein College of Medicine | N/A |
| Active Not Recruiting | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian NCT02208375 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopi NCT01970722 | City of Hope Medical Center | Phase 1 |
| Unknown | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or NCT02065687 | Gynecologic Oncology Group | Phase 2 / Phase 3 |
| Completed | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01642082 | Gynecologic Oncology Group | Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01225887 | Gynecologic Oncology Group | Phase 2 |
| Completed | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer NCT01440998 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer NCT01210222 | Gynecologic Oncology Group | Phase 2 |
| Completed | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer NCT01307631 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Prognostic Biomarkers in Patients With Endometrial Cancer NCT01208467 | Gynecologic Oncology Group | — |
| Completed | Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Pa NCT01098630 | Gynecologic Oncology Group | — |
| Completed | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01132820 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer NCT01164735 | Gynecologic Oncology Group | — |
| Withdrawn | Biomarkers in Samples From Patients With Endometrial Cancer NCT01199250 | Gynecologic Oncology Group | — |
| Completed | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Isl NCT01010126 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01011933 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00888173 | Gynecologic Oncology Group | Phase 2 |
| Completed | Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00820898 | Gynecologic Oncology Group | Phase 2 |
| Completed | Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persi NCT00729586 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV En NCT00575952 | Gynecologic Oncology Group | Phase 1 |
| Completed | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer NCT00478426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tum NCT00410553 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer NCT00006903 | Gynecologic Oncology Group | Phase 2 |
| Completed | Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus NCT00064025 | Gynecologic Oncology Group | Phase 2 |
| Completed | Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With S NCT00063999 | GOG Foundation | Phase 3 |
| Completed | Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer NCT00027690 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer NCT00006089 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Collecting Tumor Samples From Patients With Gynecological Tumors NCT00897442 | Gynecologic Oncology Group | — |